BioInvent Announces Additional Efficacy Data from Intravenous Part of Phase 1/2 Trial with BI-1206 in Solid Tumors

BioInvent announces additional efficacy data from Phase 1/2 trial with BI-1206 in solid tumors, including one patient with long-lasting stable disease and another experiencing a partial response. The study is testing the novel anti-FcyRIIB antibody in combination with pembrolizumab for patients who have previously progressed on PD-1/PD-L1 immune checkpoint inhibitors. The results suggest that BI..